Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 3:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
COVID-19, SARS-CoV-2
Interventions
CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg), CV2CoV (12 µg), CV2CoV (16 µg), CV2CoV (20 µg)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
24
States / cities
Aurora, Colorado • Hallandale, Florida • Lakeland, Florida + 11 more
Conditions
Dermatitis Atopic
Interventions
Dupilumab SAR231893
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 11 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Denver, Colorado
Conditions
Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Neoplasms by Histologic Type, Neoplasms, Clear-cell Metastatic Renal Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Bladder Cancer, Head and Neck Cancer, Non-small Cell Lung Cancer
Interventions
Combination of Varlilumab and Atezolizumab
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York + 1 more
Conditions
Solid Tumors
Interventions
I-131-CLR1404
Drug
Lead sponsor
Cellectar, Inc
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Duarte, California • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Conditions
Chronic Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
52
States / cities
Phoenix, Arizona • Encino, California • Fullerton, California + 47 more
Conditions
Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome
Interventions
Tiratricol, Placebo
Drug
Lead sponsor
Rare Thyroid Therapeutics International AB
Industry
Eligibility
4 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Kissimmee, Florida • Atlanta, Georgia • St Louis, Missouri + 3 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Batefenterol + Fluticasone Furoate, Placebo, Albuterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions
bosentan
Drug
Lead sponsor
Rajan Saggar
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Los Angeles, California
Completed No phase listed Observational Accepts healthy volunteers

Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis

NCT02559869
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
[18F] GE-180
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Conditions
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Interventions
MSC2156119J
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Gaucher Disease Type 1, Gaucher Disease Type 3
Interventions
venglustat (GZ402671), imiglucerase
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
New Haven, Connecticut • Dallas, Texas • Fairfax, Virginia
Conditions
Stroke
Interventions
Magnesium Chloride, Placebo
Drug
Lead sponsor
Relox Medical, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Grand Rapids, Michigan • Suffern, New York • Toledo, Ohio
Conditions
PTSD
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Tetanus
Interventions
Tetanus Immune Globulin (Human), Diphtheria-Tetanus Toxoids Adsorbed
Drug · Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
New Hyde Park, New York
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effects on Bioavailability of MDMA in Healthy Volunteers

NCT05147402
Conditions
Pharmacokinetics
Interventions
midomafetamine
Drug
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Cancer
Interventions
MEDI-575
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Denver, Colorado • Indianapolis, Indiana • Las Vegas, Nevada + 2 more
Completed No phase listed Observational Accepts healthy volunteers

Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury

NCT02266563
Conditions
Traumatic Brain Injury, Chronic Traumatic Encephalopathy, Mild Cognitive Impairment
Interventions
Amyvid PET Scan, T807 PET scan
Drug
Lead sponsor
Samuel Gandy
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1986 – 1994
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Healthy
Interventions
Midazolam, PD-0332991
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
South Miami, Florida
Conditions
NAFLD
Interventions
Dietary intervention with very low calorie diet (VLCD), Control Arm
Dietary Supplement · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin, Carcinoma
Interventions
Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose, Part 2: VP-315 2 Day Dosing/Week - Split Dose, Part 2: VP-315 3 Day Dosing/Week - Split Dose
Drug
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
San Diego, California • Boca Raton, Florida • Coral Springs, Florida + 9 more
Conditions
Haemophilia A, Haemophilia A With Inhibitors
Interventions
NNC0365-3769 (Mim8)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 28 more
Conditions
Peyronie's Disease
Interventions
Subjects Previously Treated with AA4500
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 90 Years · Male only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Anchorage, Alaska • Burbank, California • Laguna Hills, California + 27 more
Conditions
Anemia, Mortality
Interventions
Early anemia diagnosis and treatment, No change from normal routine
Other
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Denver, Colorado • Jacksonville, Florida • Chicago, Illinois + 33 more